
Higher levels of lipoprotein(a) (Lp[a]) were found to be associated with a continuously increasing risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events.

Hayden is an associate editor for The American Journal of Managed Care® (AJMC®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.

Higher levels of lipoprotein(a) (Lp[a]) were found to be associated with a continuously increasing risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events.

A collection of research by Helen Hobbs, MD, highlights how genetic mutations influence cholesterol levels and impact heart disease risk, offering insights into lifelong cardiovascular health management.

On day 1 of the Family Heart Global Summit, speakers highlighted the critical need for awareness, early diagnosis, and innovative treatment options for familial hypercholesterolemia, sharing significant strides made in the field over the past decade.

Domestic and international financial challenges in maternity care highlight the need for payment reforms to reduce out-of-pocket costs and better protect pregnant women from financial strain.

Weight loss drugs have gained attention as a tool to help combat obesity, but understanding how they work, who they’re for, and their potential downsides is key to making informed decisions.

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary fibrosis (IPF).

Introducing artificial intelligence (AI)–powered robots like AMECA into health care comes with potential benefits like improved clinical decision-making and faster diagnoses, but also presents challenges such as misinformation risks and data privacy concerns.

Luca Richeldi, MD, PhD, outlined crucial lessons from recent idiopathic pulmonary fibrosis (IPF) trial failures, advocating for adaptive trial designs, rigorous statistical methods, and a focus on patient-relevant outcomes to enhance future research.

Sulthiame demonstrated significant reductions in respiratory pauses and improvements in oxygen levels during sleep, offering hope for patients with obstructive sleep apnea who cannot use continuous positive airway pressure machines.

Speakers at the European Respiratory Society Congress 2024 provided updates to the 2 trials focusing on depemokimab for severe asthma and dupilumab for pediatric asthma.

New findings highlight the potential role of artificial intelligence in supporting health care professionals, but thorough testing is needed before its integration into everyday clinical practice.

A pair of studies presented at the European Respiratory Society Congress 2024 emphasized the importance of close monitoring and proactive treatment approaches for patients with idiopathic (IPF) and progressive pulmonary fibrosis (PPF).

Speakers at the European Respiratory Society Congress 2024 highlighted the potential of artificial intelligence (AI) in transforming respiratory health care, while also raising important ethical concerns related to autonomy, equity, transparency, and sustainability.

The European Respiratory Society (ERS) Congress 2024 will delve into the balance between human expertise and the growing role of artificial intelligence (AI) in respiratory medicine.

New findings add to the relationship between red meat and processed meat consumption and the risk of type 2 diabetes.

“It's not unusual for complex disorders to have combination therapies,” says Martin Kolb, MD, PhD, professor of medicine at McMaster University.

Martin Kolb, MD, PhD, highlights the importance of taking time to explain the complexities of idiopathic pulmonary fibrosis (IPF) to patients before starting long-term treatment.

The expanded approval for the Omnipod 5 system now allows automated insulin delivery (AID) for adults with type 2 diabetes, offering a new option for better glucose management without daily injections.

The $2.49 billion cash purchase will give McKesson about 70% ownership of Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures).

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes.

New research indicates that the heart benefits of semaglutide can extend to those with heart failure.

Heart failure mortality rates after hospital discharge have seen little improvement since 2010 among Medicare beneficiaries, with real-world outcomes falling short of clinical trial expectations.

New findings point to a 6% decrease in mortality risk for each unit increase in body mass index (BMI).

The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer.

Diabetic macular edema treatment options include anti-vascular endothelial growth factor (anti-VEGF) injections and laser therapy, with patient-specific factors guiding the best approach.

The current outbreak stems from the clade I strain of mpox, different from the clade II strain that caused the 2022 global health emergency.

At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care®, experts discussed efforts to implement obesity management science into practice.

Early intervention for idiopathic pulmonary fibrosis (IPF) is crucial due to the high mortality rate, with emerging therapies like nerandomilast showing potential to reduce health care costs by preventing disease progression.

Despite guidelines recommending annual screenings, nearly half of patients with diabetes miss critical eye exams, explains Jose A. Martinez, MD, president and retina specialist at Austin Retina Associates.

A new study found that older patients with atrial functional mitral regurgitation who underwent mitral valve surgery had significantly better outcomes than those who received medical management alone, including lower rates of heart failure hospitalization and death.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
